The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Radionuclide Drug Conjugates (RDC) Market Research Report 2024

Global Radionuclide Drug Conjugates (RDC) Market Research Report 2024

Publishing Date : Jul, 2023

License Type :
 

Report Code : 1763579

No of Pages : 99

Ask Your Query

Synopsis
Global Radionuclide Drug Conjugates (RDC) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Radionuclide Drug Conjugates (RDC) market research.

RDC therapy combines radionuclides with specific monoclonal antibodies to achieve the dual advantages of precise targeting and powerful killing of tumor cells. It can highly concentrate the energy released by radionuclides within several times the diameter of cancer cells, thereby minimizing damage to surrounding normal tissues. This enables it to effectively kill cancer cells while protecting normal tissues, so it has good curative effect and low adverse reactions, and can prolong the survival of patients with advanced cancer, which is of great significance to the treatment of advanced tumors.

According to the function, RDC can be divided into RDC for diagnosis and RDC for treatment, and the functional classification is closely related to the type of nuclide.

At present, the most widely used nuclide for diagnosis is 99mTc, and the nuclide for treatment is 131I, 90Y and 223Ra. Radionuclide technology provides unique advantages for early diagnosis and targeted therapy of tumors, but the acquisition and preparation technology of radionuclide still limits its wider clinical application and needs further research and development.

According to different targeting ligands, RDC can be subdivided into: antibody-conjugated nuclide drugs (ARC) and small molecule-conjugated nuclide drugs (including polypeptide-conjugated nuclide drugs-PRC).

According to the data of the Global New Drug Information Database, among the RDC drugs currently in clinical research and on the market, the main research targets are CAIX (carbonic anhydrase IX), PSMA (prostate-specific membrane antigen), SSTR (somatostatin receptor ); the main indications are concentrated in neuroendocrine tumors, prostate cancer, and renal cell carcinoma.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Radionuclide Drug Conjugates (RDC) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • POINT Biopharma
  • Telix
  • ITM AG
  • Bayer AG
  • Novartis
  • Lantheus
  • Curium Pharma
  • Uihc Pet Imaging
  • Grand Pharma
  • BoomRay Pharmaceuticals
  • SmartNuclide Biopharma
  • Hengrui Medicine
  • Yunnan Baiyao Group
  • Sinotau
  • Hexin Pharmaceutical
  • Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.

Segment by Type

  • Antibody Radionuclide Conjugates (ARC)
  • Peptide Radionuclide Conjugates (PRC)
  • Small Molecular Radionuclide Conjugates (SMRC)

Segment by Application

  • Neuroendocrine Tumors
  • Prostate Cancer
  • Renal Cell Carcinoma

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
  • Latin America (Mexico, Brazil, Rest of Latin America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)

The Radionuclide Drug Conjugates (RDC) report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Antibody Radionuclide Conjugates (ARC)
1.2.3 Peptide Radionuclide Conjugates (PRC)
1.2.4 Small Molecular Radionuclide Conjugates (SMRC)
1.3 Market by Application
1.3.1 Global Radionuclide Drug Conjugates (RDC) Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Neuroendocrine Tumors
1.3.3 Prostate Cancer
1.3.4 Renal Cell Carcinoma
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Radionuclide Drug Conjugates (RDC) Market Perspective (2018-2029)
2.2 Radionuclide Drug Conjugates (RDC) Growth Trends by Region
2.2.1 Global Radionuclide Drug Conjugates (RDC) Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Radionuclide Drug Conjugates (RDC) Historic Market Size by Region (2018-2023)
2.2.3 Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Region (2024-2029)
2.3 Radionuclide Drug Conjugates (RDC) Market Dynamics
2.3.1 Radionuclide Drug Conjugates (RDC) Industry Trends
2.3.2 Radionuclide Drug Conjugates (RDC) Market Drivers
2.3.3 Radionuclide Drug Conjugates (RDC) Market Challenges
2.3.4 Radionuclide Drug Conjugates (RDC) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Radionuclide Drug Conjugates (RDC) Players by Revenue
3.1.1 Global Top Radionuclide Drug Conjugates (RDC) Players by Revenue (2018-2023)
3.1.2 Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Players (2018-2023)
3.2 Global Radionuclide Drug Conjugates (RDC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Radionuclide Drug Conjugates (RDC) Revenue
3.4 Global Radionuclide Drug Conjugates (RDC) Market Concentration Ratio
3.4.1 Global Radionuclide Drug Conjugates (RDC) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radionuclide Drug Conjugates (RDC) Revenue in 2022
3.5 Radionuclide Drug Conjugates (RDC) Key Players Head office and Area Served
3.6 Key Players Radionuclide Drug Conjugates (RDC) Product Solution and Service
3.7 Date of Enter into Radionuclide Drug Conjugates (RDC) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Radionuclide Drug Conjugates (RDC) Breakdown Data by Type
4.1 Global Radionuclide Drug Conjugates (RDC) Historic Market Size by Type (2018-2023)
4.2 Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Type (2024-2029)
5 Radionuclide Drug Conjugates (RDC) Breakdown Data by Application
5.1 Global Radionuclide Drug Conjugates (RDC) Historic Market Size by Application (2018-2023)
5.2 Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
6.2 North America Radionuclide Drug Conjugates (RDC) Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023)
6.4 North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
7.2 Europe Radionuclide Drug Conjugates (RDC) Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023)
7.4 Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
8.2 Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size by Region (2018-2023)
8.4 Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
9.2 Latin America Radionuclide Drug Conjugates (RDC) Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023)
9.4 Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size (2018-2029)
10.2 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023)
10.4 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 POINT Biopharma
11.1.1 POINT Biopharma Company Detail
11.1.2 POINT Biopharma Business Overview
11.1.3 POINT Biopharma Radionuclide Drug Conjugates (RDC) Introduction
11.1.4 POINT Biopharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.1.5 POINT Biopharma Recent Development
11.2 Telix
11.2.1 Telix Company Detail
11.2.2 Telix Business Overview
11.2.3 Telix Radionuclide Drug Conjugates (RDC) Introduction
11.2.4 Telix Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.2.5 Telix Recent Development
11.3 ITM AG
11.3.1 ITM AG Company Detail
11.3.2 ITM AG Business Overview
11.3.3 ITM AG Radionuclide Drug Conjugates (RDC) Introduction
11.3.4 ITM AG Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.3.5 ITM AG Recent Development
11.4 Bayer AG
11.4.1 Bayer AG Company Detail
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Radionuclide Drug Conjugates (RDC) Introduction
11.4.4 Bayer AG Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.4.5 Bayer AG Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Radionuclide Drug Conjugates (RDC) Introduction
11.5.4 Novartis Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.5.5 Novartis Recent Development
11.6 Lantheus
11.6.1 Lantheus Company Detail
11.6.2 Lantheus Business Overview
11.6.3 Lantheus Radionuclide Drug Conjugates (RDC) Introduction
11.6.4 Lantheus Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.6.5 Lantheus Recent Development
11.7 Curium Pharma
11.7.1 Curium Pharma Company Detail
11.7.2 Curium Pharma Business Overview
11.7.3 Curium Pharma Radionuclide Drug Conjugates (RDC) Introduction
11.7.4 Curium Pharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.7.5 Curium Pharma Recent Development
11.8 Uihc Pet Imaging
11.8.1 Uihc Pet Imaging Company Detail
11.8.2 Uihc Pet Imaging Business Overview
11.8.3 Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Introduction
11.8.4 Uihc Pet Imaging Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.8.5 Uihc Pet Imaging Recent Development
11.9 Grand Pharma
11.9.1 Grand Pharma Company Detail
11.9.2 Grand Pharma Business Overview
11.9.3 Grand Pharma Radionuclide Drug Conjugates (RDC) Introduction
11.9.4 Grand Pharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.9.5 Grand Pharma Recent Development
11.10 BoomRay Pharmaceuticals
11.10.1 BoomRay Pharmaceuticals Company Detail
11.10.2 BoomRay Pharmaceuticals Business Overview
11.10.3 BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Introduction
11.10.4 BoomRay Pharmaceuticals Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.10.5 BoomRay Pharmaceuticals Recent Development
11.11 SmartNuclide Biopharma
11.11.1 SmartNuclide Biopharma Company Detail
11.11.2 SmartNuclide Biopharma Business Overview
11.11.3 SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Introduction
11.11.4 SmartNuclide Biopharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.11.5 SmartNuclide Biopharma Recent Development
11.12 Hengrui Medicine
11.12.1 Hengrui Medicine Company Detail
11.12.2 Hengrui Medicine Business Overview
11.12.3 Hengrui Medicine Radionuclide Drug Conjugates (RDC) Introduction
11.12.4 Hengrui Medicine Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.12.5 Hengrui Medicine Recent Development
11.13 Yunnan Baiyao Group
11.13.1 Yunnan Baiyao Group Company Detail
11.13.2 Yunnan Baiyao Group Business Overview
11.13.3 Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Introduction
11.13.4 Yunnan Baiyao Group Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.13.5 Yunnan Baiyao Group Recent Development
11.14 Sinotau
11.14.1 Sinotau Company Detail
11.14.2 Sinotau Business Overview
11.14.3 Sinotau Radionuclide Drug Conjugates (RDC) Introduction
11.14.4 Sinotau Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.14.5 Sinotau Recent Development
11.15 Hexin Pharmaceutical
11.15.1 Hexin Pharmaceutical Company Detail
11.15.2 Hexin Pharmaceutical Business Overview
11.15.3 Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Introduction
11.15.4 Hexin Pharmaceutical Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.15.5 Hexin Pharmaceutical Recent Development
11.16 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.
11.16.1 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Company Detail
11.16.2 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Business Overview
11.16.3 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Introduction
11.16.4 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.16.5 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock